Tumor necrosis factor mediates temporomandibular joint bone tissue resorption in rheumatoid arthritis

References

• Tegelberg A, Kopp S. Subjective symptoms from the stomatognathic system in individuals with rheumatoid arthritis and osteoarthrosis. Swed Dent J 1987;11:11–22.
   PubMedGoogle Scholar
• Jacox A. Overview of osteoarthritis, rheumatoid arthritis, juvenile chronic arthritis, and related pain. In Jacox A, editors. Guideline for the management of pain on osteoarthritis, rheumatoid arthritis, and juvenile chronic arthritis. Glenview, IL: American Pain Society; 2002. p 1–9.
   Google Scholar
• Nordahl S, Alstergren P, Eliasson S, Kopp S. Radiographic signs of bone destruction in the arthritic temporomandibular joint with special reference to markers of disease activity. A longitudinal study. Rheumatol (Oxf) 2001;40:691–4.
   PubMed Web of Science ®Google Scholar
• Akerman S, Jonsson K, Kopp S, Petersson A, Rohlin M. Radiologic changes in temporomandibular, hand, and foot joints of patients with rheumatoid arthritis. Oral Surg Oral Med Oral Pathol 1991;72:245–50.
   PubMedGoogle Scholar
• Smith HJ, Larheim TA, Aspestrand F. Rheumatic and nonrheumatic disease in the temporomandibular joint: gadolinium-enhanced MR imaging. Radiology 1992;185:229–34.
   PubMed Web of Science ®Google Scholar
• Suenaga S, Ogura T, Matsuda T, Noikura T. Severity of synovium and bone marrow abnormalities of the temporomandibular joint in early rheumatoid arthritis: role of gadolinium-enhanced fat-suppressed T1-weighted spin echo MRI. J Comput Assist Tomogr 2000;24:461–5.
   PubMed Web of Science ®Google Scholar
• Hajati AK, Nasstrom K, Alstergren P, Bratt J, Kopp S. Temporomandibular joint bone tissue resorption in patients with early rheumatoid arthritis can be predicted by joint crepitus and plasma glutamate level. Mediators Inflamm 2010;2010:627803.
   PubMed Web of Science ®Google Scholar
• Hajati AK, Alstergren P, Nasstrom K, Bratt J, Kopp S. Endogenous glutamate in association with inflammatory and hormonal factors modulates bone tissue resorption of the temporomandibular joint in patients with early rheumatoid arthritis. J Oral Maxillofac Surg 2009;67:1895–903.
   PubMedGoogle Scholar
• Voog U, Alstergren P, Eliasson S, Leibur E, Kallikorm R, Kopp S. Inflammatory mediators and radiographic changes in temporomandibular joints of patients with rheumatoid arthritis. Acta Odontol Scand 2003;61:57–64.
   PubMed Web of Science ®Google Scholar
• Kretapirom K, Okochi K, Nakamura S, Tetsumura A, Ohbayashi N, Yoshino N, et al. MRI characteristics of rheumatoid arthritis in the temporomandibular joint. Dentomaxillofac Radiol 2013;42:31627230.
   PubMedGoogle Scholar
• Emshoff R, Puffer P, Rudisch A, Gassner R. Temporomandibular joint pain: relationship to internal derangement type, osteoarthrosis, and synovial fluid mediator level of tumor necrosis factor-alpha. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:442–9.
   PubMedGoogle Scholar
• van de Loo FA, Joosten LA, van Lent PL, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995;38:164–72.
   PubMed Web of Science ®Google Scholar
• Kaneyama K, Segami N, Sun W, Sato J, Fujimura K. Levels of soluble cytokine factors in temporomandibular joint effusions seen on magnetic resonance images. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99:411–18.
   PubMedGoogle Scholar
• Kaneyama K, Segami N, Nishimura M, Suzuki T, Sato J. Importance of proinflammatory cytokines in synovial fluid from 121 joints with temporomandibular disorders. Br J Oral Maxillofac Surg 2002;40:418–23.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Segami N, Nishimura M, Nojima T. Co-expression of interleukin-1beta and tumor necrosis factor alpha in synovial tissues and synovial fluids of temporomandibular joint with internal derangement: comparison with histological grading of synovial inflammation. J Oral Pathol Med 2002;31:549–57.
   PubMedGoogle Scholar
• Brennan FM, Maini RN, Feldmann M. Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol 1998;20:133–47.
   PubMed Web of Science ®Google Scholar
• Watkins LR, Wiertelak EP, Goehler LE, Smith KP, Martin D, Maier SF. Characterization of cytokine-induced hyperalgesia. Brain Res 1994;654:15–26.
   PubMed Web of Science ®Google Scholar
• Duff GW. Cytokines and acute phase proteins in rheumatoid arthritis. Scand J Rheumatol Suppl 1994;100:9–19.
   PubMedGoogle Scholar
• Sandler NA, Buckley MJ, Cillo JE, Braun TW. Correlation of inflammatory cytokines with arthroscopic findings in patients with temporomandibular joint internal derangements. J Oral Maxillofac Surg 1998;56:534–43.
   PubMed Web of Science ®Google Scholar
• Nordahl S, Alstergren P, Eliasson S, Kopp S. Interleukin-1beta in plasma and synovial fluid in relation to radiographic changes in arthritic temporomandibular joints. Eur J Oral Sci 1998;106:559–63.
   PubMed Web of Science ®Google Scholar
• North J, Situnayake RD, Tikly M, Cremona A, Nicoll J, Kumararatne DS, et al. Interleukin 1 beta, hand and foot bone mineral content and the development of joint erosions in rheumatoid arthritis. Ann Rheum Dis 1994;53:543–6.
   PubMedGoogle Scholar
• Jouvenne P, Vannier E, Dinarello CA, Miossec P. Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. Arthritis Rheum 1998;41:1083–9.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095–147.
   PubMed Web of Science ®Google Scholar
• Olsson I. The cytokine network. J Intern Med 1993;233:103–5.
   PubMedGoogle Scholar
• Alstergren P, Larsson PT, Kopp S. Successful treatment with multiple intra-articular injections of infliximab in a patient with psoriatic arthritis. Scand J Rheumatol 2008;37:155–7.
   PubMed Web of Science ®Google Scholar
• Burska A, Boissinot M, Ponchel F. Cytokines as biomarkers in rheumatoid arthritis. Mediators Inflamm 2014;545493.
   PubMedGoogle Scholar
• Kocijan R, Harre U, Schett G. ACPA and bone loss in rheumatoid arthritis. Curr Rheumatol Rep 2013;15:366.
   PubMedGoogle Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Voog U, Alstergren P, Leibur E, Kallikorm R, Kopp S. Impact of temporomandibular joint pain on activities of daily living in patients with rheumatoid arthritis. Acta Odontol Scand 2003;61:278–82.
   PubMed Web of Science ®Google Scholar
• Leeb BF, Andel I, Sautner J, Nothnagl T, Rintelen B. The DAS28 in rheumatoid arthritis and fibromyalgia patients. Rheumatol (Oxf) 2004;43:1504–7.
   PubMed Web of Science ®Google Scholar
• Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatol (Oxf) 2004;43:1252–5.
   PubMed Web of Science ®Google Scholar
• Alstergren P, Kopp S, Theodorsson E. Synovial fluid sampling from the temporomandibular joint: sample quality criteria and levels of interleukin-1 beta and serotonin. Acta Odontol Scand 1999;57:16–22.
   PubMed Web of Science ®Google Scholar
• Ahmad M, Hollender L, Anderson Q, Kartha K, Ohrbach R, Truelove EL, et al. Research diagnostic criteria for temporomandibular disorders (RDC/TMD): development of image analysis criteria and examiner reliability for image analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107:844–60.
   PubMed Web of Science ®Google Scholar
• Alstergren P, Kopp S. Insufficient endogenous control of tumor necrosis factor-alpha contributes to temporomandibular joint pain and tissue destruction in rheumatoid arthritis. J Rheumatol 2006;33:1734–9.
   PubMed Web of Science ®Google Scholar
• Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323–9.
   PubMed Web of Science ®Google Scholar
• Voog U, Alstergren P, Eliasson S, Leibur E, Kallikorm R, Kopp S. Progression of radiographic changes in the temporomandibular joints of patients with rheumatoid arthritis in relation to inflammatory markers and mediators in the blood. Acta Odontol Scand 2004;62:7–13.
   PubMed Web of Science ®Google Scholar
• Maizlin ZV, Nutiu N, Dent PB, Vos PM, Fenton DM, Kirby JM, et al. Displacement of the temporomandibular joint disk: correlation between clinical findings and MRI characteristics. J Can Dent Assoc 2010;76:a3.
   PubMedGoogle Scholar
• Molinari F, Manicone PF, Raffaelli L, Raffaelli R, Pirronti T, Bonomo L. Temporomandibular joint soft-tissue pathology, I: Disc abnormalities. Semin Ultrasound CT MR 2007;28:192–204.
   PubMedGoogle Scholar
• Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van’t Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831–5.
   PubMed Web of Science ®Google Scholar
• Mustila A, Korpela M, Haapala AM, Kautiainen H, Laasonen L, Mottonen T, et al. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease–modifying antirheumatic drug strategies. Clin Exp Rheumatol 2011;29:500–5.
   PubMedGoogle Scholar
• Choe JY, Bae J, Lee H, Bae SC, Kim SK. Relation of rheumatoid factor and anti-cyclic citrullinated peptide antibody with disease activity in rheumatoid arthritis: cross-sectional study. Rheumatol Int 2013;33:2373–9.
   PubMedGoogle Scholar
• Seegobin SD, Ma MH, Dahanayake C, Cope AP, Scott DL, Lewis CM, et al. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial. Arthritis Res Ther 2014;16:R13.
   PubMed Web of Science ®Google Scholar
• Mosaad YM, Hammad EM, Fawzy Z, Abdal Aal IA, Youssef HM, ElSaid TO, et al. Vitamin D receptor gene polymorphism as possible risk factor in rheumatoid arthritis and rheumatoid related osteoporosis. Hum Immunol 2014;75:452–61.
   PubMed Web of Science ®Google Scholar
• Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999;163:1521–8.
   PubMed Web of Science ®Google Scholar
• Matcham F, Scott IRayner L, Hotopf M, Kingsley GH, Norton S, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: A systematic review and meta-analysis. Semin Arthritis Rheum 2014;44:123–30.
   PubMed Web of Science ®Google Scholar